Dustin R. Carr
Dustin R. Carr has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Derek N. Bremmer
Department of Pharmacy, Allegheny Health Network, Pittsburgh, PA, USA
2 shared publications - Matthew A. Moffa
Medicine Institute and Division of Infectious Diseases, Allegheny Health Network, Pittsburgh, PA, United States
2 shared publications - Nathan R. Shively
Allegheny Health Network , Pittsburgh, Pennsylvania
2 shared publications - Thomas L. Walsh
Allegheny Health Network , Pittsburgh, Pennsylvania
2 shared publications Aaron Thomas
Division of Infectious Diseases
1 shared publication- Carley Buchanan
Department of Pharmacy, West Penn Hospital, Allegheny Health Network, 4800 Friendship Ave, Pittsburgh, PA 15224, USA
1 shared publication
Latest Publications
- 1 November 2022
- Published by Wolters Kluwer Health in Infectious Diseases in Clinical Practice
- Vol. 30 (6) , 1-6
Impact of Convalescent Plasma Therapy in Hospitalized Patients With Severe COVID-19
Background Convalescent plasma (CP) is often administered to hospitalized patients with COVID-19, but the impact on clinical outcomes has varied across different patient populations. Methods A retrospective, propensity score–matched controlled study was conducted to compare outcomes of hospitalized patients with nonmechanically ventilated severe COVID-19 who received CP within 36 hours of hospital admission with those who did not receive CP during their hospitalization. A combination of propensity score matching and Mahalanobis distance matching was used. Results One hundred forty-three patients were originally in the treatment group, and 94 were able to be matched to control patients who did not receive CP during their hospital stay. Receipt of early CP was not associated with significant differences in clinical outcomes. Overall 30-day mortality was 12.8% in the CP group and 14.9% in the non-CP group (P = 0.67). No significant differences were observed between the early CP group and the non-CP group for 30-day readmissions (12.8% vs 9.6%; P = 0.47), subsequent transfer to an intensive care unit (2.1% vs 2.1%; P = 1.0), and subsequent progression to noninvasive ventilation after 36 hours from admission (12.8% vs 5.3%; P = 0.07). Receipt of early CP was associated with increased need for mechanical ventilation after 36 hours from admission (12.8% vs 3.2%; P = 0.013). Conclusions Receipt of early CP for hospitalized patients with severe COVID-19 but not requiring mechanical ventilation was not associated with improvements in clinical status or mortality compared with matched patients who did not receive CP.
- 1 November 2022
- Published by Wolters Kluwer Health in Infectious Diseases in Clinical Practice
- Vol. 30 (6) , 1-6
Impact of Convalescent Plasma Therapy in Hospitalized Patients With Severe COVID-19
Background Convalescent plasma (CP) is often administered to hospitalized patients with COVID-19, but the impact on clinical outcomes has varied across different patient populations. Methods A retrospective, propensity score–matched controlled study was conducted to compare outcomes of hospitalized patients with nonmechanically ventilated severe COVID-19 who received CP within 36 hours of hospital admission with those who did not receive CP during their hospitalization. A combination of propensity score matching and Mahalanobis distance matching was used. Results One hundred forty-three patients were originally in the treatment group, and 94 were able to be matched to control patients who did not receive CP during their hospital stay. Receipt of early CP was not associated with significant differences in clinical outcomes. Overall 30-day mortality was 12.8% in the CP group and 14.9% in the non-CP group (P = 0.67). No significant differences were observed between the early CP group and the non-CP group for 30-day readmissions (12.8% vs 9.6%; P = 0.47), subsequent transfer to an intensive care unit (2.1% vs 2.1%; P = 1.0), and subsequent progression to noninvasive ventilation after 36 hours from admission (12.8% vs 5.3%; P = 0.07). Receipt of early CP was associated with increased need for mechanical ventilation after 36 hours from admission (12.8% vs 3.2%; P = 0.013). Conclusions Receipt of early CP for hospitalized patients with severe COVID-19 but not requiring mechanical ventilation was not associated with improvements in clinical status or mortality compared with matched patients who did not receive CP.
- Open Access
- 26 May 2020
- Published by MDPI AG in Antibiotics
- Vol. 9 (6) , 282
Impact of a Multiplex Polymerase Chain Reaction Assay on the Clinical Management of Adults Undergoing a Lumbar Puncture for Suspected Community-Onset Central Nervous System Infections
Patients admitted from the community with a suspected central nervous system (CNS) infection require prompt diagnostic evaluation and correct antimicrobial treatment. A retrospective, multicenter, pre/post intervention study was performed to evaluate the impact that the BioFire® FilmArray® meningitis/encephalitis (ME) panel run in-house had on the clinical management of adult patients admitted from the community with a lumbar puncture (LP) performed for a suspected CNS infection. The primary outcome was the effect that this intervention had on herpes simplex virus (HSV) polymerase chain reaction (PCR) turnaround time (TAT). Secondary outcomes included the effect that this intervention had on antiviral days of therapy (DOT), total antimicrobial DOT, and hospital length of stay (LOS). A total of 81 and 79 patients were included in the pre-intervention and post-intervention cohorts, respectively. The median HSV PCR TAT was significantly longer in the pre-intervention group (85 vs. 4.1 h, p < 0.001). Total antiviral DOT was significantly greater in the pre-intervention group (3 vs. 1, p < 0.001), as was total antimicrobial DOT (7 vs. 5, p < 0.001). Pre-intervention hospital LOS was also significantly longer (6.6 vs. 4.4 days, p = 0.02). Implementing the ME panel in-house for adults undergoing an LP for a suspected community-onset CNS infection significantly reduced the HSV PCR TAT, antiviral DOT, total antimicrobial DOT, and hospital LOS.
- 26 May 2020
- Published by MDPI AG in Antibiotics
- Vol. 9 (6) , 282
Open AccessImpact of a Multiplex Polymerase Chain Reaction Assay on the Clinical Management of Adults Undergoing a Lumbar Puncture for Suspected Community-Onset Central Nervous System Infections
Patients admitted from the community with a suspected central nervous system (CNS) infection require prompt diagnostic evaluation and correct antimicrobial treatment. A retrospective, multicenter, pre/post intervention study was performed to evaluate the impact that the BioFire® FilmArray® meningitis/encephalitis (ME) panel run in-house had on the clinical management of adult patients admitted from the community with a lumbar puncture (LP) performed for a suspected CNS infection. The primary outcome was the effect that this intervention had on herpes simplex virus (HSV) polymerase chain reaction (PCR) turnaround time (TAT). Secondary outcomes included the effect that this intervention had on antiviral days of therapy (DOT), total antimicrobial DOT, and hospital length of stay (LOS). A total of 81 and 79 patients were included in the pre-intervention and post-intervention cohorts, respectively. The median HSV PCR TAT was significantly longer in the pre-intervention group (85 vs. 4.1 h, p < 0.001). Total antiviral DOT was significantly greater in the pre-intervention group (3 vs. 1, p < 0.001), as was total antimicrobial DOT (7 vs. 5, p < 0.001). Pre-intervention hospital LOS was also significantly longer (6.6 vs. 4.4 days, p = 0.02). Implementing the ME panel in-house for adults undergoing an LP for a suspected community-onset CNS infection significantly reduced the HSV PCR TAT, antiviral DOT, total antimicrobial DOT, and hospital LOS.